Work Here?
Work Here?
Work Here?
Industries
Biotechnology
Healthcare
Company Size
10,001+
Company Stage
IPO
Total Funding
$1.2B
Headquarters
Indianapolis, Indiana
Founded
1876
Eli Lilly and Company focuses on discovering, developing, and delivering medicines that enhance health and well-being. The company has a long history of scientific achievements, including the creation of insulin, the first effective treatment for diabetes. Lilly operates in the pharmaceutical sector, creating treatments for various medical conditions such as diabetes, cancer, and pain management. Their products are sold to healthcare providers, who prescribe them to patients. Lilly invests significantly in research and development to ensure their medicines are safe and effective, setting them apart from competitors who may not prioritize R&D to the same extent. The company's goal is to improve lives through innovative medical solutions while maintaining high ethical standards and ensuring the availability of their products.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$1180.1M
Above
Industry Average
Funded Over
4 Rounds
Post IPO Debt Funding Comparison Coming Soon
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatmentNearly 90% of patients who achieved endoscopic response at one year sustained it at two yearsOmvoh is the first IL-23p19 antagonist to demonstrate multi-year, sustained efficacy and safety for both Crohn's disease and ulcerative colitisINDIANAPOLIS, Feb. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of continuous treatment with Omvoh® (mirikizumab-mrkz) achieved long-term clinical and endoscopic outcomes, including those (43.8%) with previous biologic failure. Data from this study will be presented at the Crohn's and Colitis Congress (CCC), being held from February 6-8, 2025 in San Francisco.1Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation.2,3"Many people living with Crohn's disease have tried available therapies without success or have experienced a loss of efficacy with their treatment," said Edward Barnes, M.D., MPH, Associate Professor of Medicine in the Division of Gastroenterology & Hepatology, Co-Director of the Multidisciplinary Inflammatory Bowel Diseases Center at the University of North Carolina at Chapel Hill. "These positive, multi-year data can give health care providers confidence that Omvoh may help their patients achieve and maintain long-term outcomes, including intestinal healing."Participants randomized to Omvoh in the Phase 3 VIVID-1 study who achieved endoscopic response after one year of treatment continued Omvoh maintenance treatment in VIVID-2. The following results were achieved based upon observed case analysis after two years of continuous treatment, including one year during VIVID-1:Among patients who were in clinical remission at one year in VIVID-1, 92.9% maintained clinical remission at two years as measured by Crohn's Disease Activity Index (CDAI).Among patients treated in VIVID-2, 87.6% maintained endoscopic response, defined by visible healing of the intestinal lining and measured by a ≥50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) total score.Among patients who were in endoscopic remission at one year of treatment in VIVID-1, 78.6% maintained endoscopic remission at two years as measured by SES-CD ≤4 and ≥2-point reduction from baseline, with no subscore >1 in any individual variable.1Additionally:Among patients who were not in clinical remission by CDAI at one year, 60.8% gained clinical remission during the second year of treatment.Among patients who were not in endoscopic remission at one year, 35.4% gained endoscopic remission during the second year of treatment.1These results were also evaluated using a modified non-responder imputation method, presented in the About the VIVID Clinical Trial Program section below.In VIVID-2, the long-term safety profile of Omvoh in patients with moderately to severely active Crohn's disease was generally consistent with the known safety profile of Omvoh. During the second year of continuous treatment with Omvoh, 6.8% of patients with endoscopic response at one year reported a serious adverse event and 0.8% discontinued treatment due to an adverse event.1"Lilly is setting a high bar for sustained and durable treatment response for patients living with the profound impact of inflammatory bowel disease," said Mark Genovese, M.D., senior vice president of Lilly Immunology development
Eli Lilly announced the acquisition of Scorpion Therapeutics for up to $2.5 billion, gaining rights to Scorpion's PI3Kα inhibitor program, STX-478, for breast cancer and other tumors. The deal includes an upfront payment and milestone-based payments. Scorpion will spin off a new company for its non-PI3Kα assets, led by Dr. Adam Friedman. STX-478 targets PI3Kα mutations in HR-positive HER2-negative breast cancer, offering improved efficacy and safety over existing treatments.
Adding to the deal flurry, Eli Lilly acquired a clinical oncology drug candidate from Scorpion Therapeutics for as much as $2.5 billion in milestone payments down the road.
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one yearAmong those who achieved clinical remission and endoscopic response at one year, nearly 90% of patients maintained clinical remission with two years of continuous Omvoh treatment in open-label extensionINDIANAPOLIS, Jan. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults.1Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval.2"The burden of Crohn's disease on patients' daily lives is substantial," said Michael Osso, president and chief executive officer, Crohn's & Colitis Foundation
Earlier this week, Eli Lilly said it would spend $2.5 billion to acquire a cancer drug from privately held Scorpion Therapeutics.
Eli Lilly is building a $9 billion manufacturing complex in Lebanon, Indiana, to produce key components for its GLP-1 drugs, including tirzepatide, alongside a $4.5 billion research center.
At the 2024 International Biopharmaceutical Industry Innovation Conference Beijing Forum in late October, six multinational pharmaceutical companies, including Eli Lilly, Pfizer, Bayer, AstraZeneca and Medtronic, announced plans to establish R&D or innovation projects in Beijing.
Eli Lilly has partnered with UK-based biotech Alchemab Therapeutics to develop therapeutic antibodies targeting amyotrophic lateral sclerosis (ALS), a neurodegenerative disease with limited treatment options.
US pharma major Eli Lilly and Company today said that it plans to establish a new global capability centre in Hyderabad.
Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and hire over 1,000 people to strengthen its digital strategy and service delivery.
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
10,001+
Company Stage
IPO
Total Funding
$1.2B
Headquarters
Indianapolis, Indiana
Founded
1876
Find jobs on Simplify and start your career today